Makena’s Orphan Exclusivity Is “Nullified” By FDA’s Compounding Policy, KV Suit Says
This article was originally published in The Pink Sheet Daily
KV seeks a court order requiring FDA to desist from permitting importation of unapproved API for compounded hydroxyprogesterone and to state its intent to take enforcement action against compounders.
You may also be interested in...
FDA Broke Catalyst's Orphan Exclusivity Due To Pricing, Not Clinical, Concerns, Firm Claims
Suit against agency reveals internal discussions to approve Jacobus' Ruzurgi despite Catalyst's orphan exclusivity for the same drug; Sen. Bernie Sanders urged FDA to address price of Catalyst's Firdapse (amifampridine).
DTC Price Comparisons To Get FDA Scrutiny
FDA wants to measure consumer understanding of product safety and efficacy when ads compare the prices of two drugs amid concerns they could imply the compared drugs are interchangeable.
KV’s Suit Against FDA Is Revived By Thiopental Ruling, Compounding Law
Makena legal strategy benefits from halt on importation of unapproved execution drug.